AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation
Circulation · 02.04.2024 · 149 (14) · 1102-1120
DOI: 10.1161/circulationaha.123.065546 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.04.2024. Verfasst von Jiabing Zhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (J.Z., K.J., R.X., J.F.,…. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Sirtuin 3, MicroRNAs, Diabetes Mellitus. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Diabetes is associated with cardiovascular complications. microRNAs translocate into subcellular organelles to modify genes involved in diabetic cardiomyopathy. However, functional properties of subcellular AGO2 (Argonaute2), a core member of miRNA machinery, remain elusive. METHODS: We elucidated the function and mechanism of subcellular localized AGO2 on mouse models for diabetes and diabetic cardiomyopathy. Recombinant adeno-associated virus type 9 was used to deliver AGO2 to mice through the tail vein. Cardiac structure and functions were assessed by echocardiography and catheter manometer system. RESULTS: AGO2 was decreased in mitochondria of diabetic cardiomyocytes. Overexpression of mitochondrial AGO2 attenuated diabetes-induced cardiac dysfunction. AGO2 recruited TUFM , a mitochondria translation elongation factor, to activate translation of electron transport chain subunits and decrease reactive oxygen species. Malonylation, a posttranslational modification of AGO2, reduced the importing of AGO2 into mitochondria in diabetic cardiomyopathy. AGO2 malonylation was regulated by a cytoplasmic-localized short isoform of SIRT3 through a previously unknown demalonylase function. CONCLUSIONS: Our findings reveal that the SIRT3 –AGO2– CYTB axis links glucotoxicity to cardiac electron transport chain imbalance, providing new mechanistic insights and the basis to develop mitochondria targeting therapies for diabetic cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (J.Z., K.J., R.X., J.F., Y.T., C.C., H.L., D.W.W.).
- Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, China (J.Z.).
- Department of Cardiology, Fujian Medical Center for Cardiovascular Diseases, Fujian Institute of Coronary Heart Disease, Fujian Medical University, China (J.Z.).
ORCID-Profile: Jiahui Fan, Yuyan Tang, Chen Chen, Huaping Li, Dao Wen Wang
Zitieren
APA
Zhan, J., Jin, K., Xie, R., Fan, J., Tang, Y., Chen, C., Li, H., & Wang, D. W. (2024). AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation. Circulation, 149(14), 1102-1120. https://doi.org/10.1161/circulationaha.123.065546
Vancouver
Zhan J, Jin K, Xie R, Fan J, Tang Y, Chen C, et al. AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation. Circulation. 2024;149(14):1102-1120. doi:10.1161/circulationaha.123.065546
BibTeX
@article{Zhan2024,
author = {Zhan, Jiabing and Jin, Kunying and Xie, Rong and Fan, Jiahui and Tang, Yuyan and Chen, Chen and Li, Huaping and Wang, Dao Wen},
title = {AGO2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation},
journal = {Circulation},
year = {2024},
volume = {149},
number = {14},
pages = {1102--1120},
doi = {10.1161/circulationaha.123.065546}
}
EUVIMED